Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07743723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IOV-5001 in Adults With Advanced Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 0 to 1 Start date: Aug 2026 to Sep 2026 · Eligibility criteria expanded, about 18 words Show 2 more changesShow less
    • Start date: Aug 2026 to Sep 2026
    • Eligibility criteria expanded, about 18 words
  2. Secondary endpoints: details revised at 1 of 7 entriesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Iovance Biotherapeutics
12 trials monitored
See 1 trial at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
and 3 more diseases
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
Trial Details
NCT Number NCT07743723
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
Enrollment 106 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov